新闻
SAGE
--
0.00%
--
摩根士丹利维持鼠尾草疗法的均等权重,将目标股价提高至87美元
Morgan Stanley analyst Matthew Harrison maintains Sage Therapeutics (NASDAQ:SAGE) with a Equal-Weight and raises the price target from $83 to $87.
Benzinga · 2天前
分析师提供有关医疗保健公司的见解:SAGE Therapeutics(SAGE)和Paratek Pharmaceuticals(PRTK)
SmarterAnalyst · 3天前
顶级分析师升级和降级:AIG,百思买,Carvana,戴尔,惠普,Monster Beverage,Twitter,Zscaler等
247WallSt.com · 6天前
为什么瑞穗证券降低了SAGE Therapeutics的股票评级?
SAGE Therapeutics (SAGE) received a Hold rating and an $81.00 price target from Mizuho Securities analyst Vamil Divan today. The company's shares closed
SmarterAnalyst · 6天前
AT&T,Expedia,Mattel,城市服装店以及更多周四下午的分析师电话
247WallSt.com · 02/25 17:17
每日生物技术动向:博士伦与伊坎(Icahn)休战,辉瑞公司的脑炎疫苗获得优先审查,BriaCell IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 23)
Benzinga · 02/24 12:30
生物技术的一周提前:强生疫苗Adcom会议,Sarepta FDA决定和大量收入
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week.
Benzinga · 02/20 14:36
Biogen在其阿尔茨海默氏症药物方面大放异彩。股票将根据FDA的决定而上涨或下跌。
If the FDA approves aducanumab, Wall Street expects Biogen’s shares to climb as much as 70%. The consequences of failure are nearly as stark.
Barrons.com · 02/05 12:01
顶级分析师升级和降级:Avaya,戴尔,On Semi,Neurocrine Bio,Palo Alto,Ping,Poshmark,Switch等
247WallSt.com · 02/02 13:54
SAGE Therapeutics的首席创新官正在行使选择权
Yesterday it was reported that the Chief Innovation Officer of SAGE Therapeutics (SAGE), Jeffrey Jonas, exercised options to buy 1,800 SAGE shares at
SmarterAnalyst · 01/29 04:01
每日生物技术动向:DBV的FDA积极反馈,辉瑞的抗癌药获得标签扩展,应用的DNA COVID检测量激增
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 14)
Benzinga · 01/15 12:57
每日生物技术脉动:Alexion暂停COVID-19研究,NantKwest读数,器官发生在指导下跳跃,试验更新
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 13)
Benzinga · 01/14 12:56
每日生物技术动向:博士伦健康发布积极的预公告,Acorda简化运营
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12)
Benzinga · 01/13 12:25
每日生物技术动向:Sarepta基因疗法研究报告,Novavax疫苗供应交易,2次IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 7)
Benzinga · 01/08 12:25
全球最大的“长Covid”研究发现,许多患者六个月后无法重返工作岗位
Recent studies have shown a growing number of patients with Covid-19 experience persistent symptoms.
CNBC.com · 01/05 23:49
Benzinga的顶级升级,降级至2021年1月4日
Upgrades * B of A Securities upgraded the previous rating for Expedia Group Inc (NASDAQ:EXPE) from Neutral to Buy. For the third quarter, Expedia Group had an EPS of $0.24, compared to year-ago quarter EPS of $3.37. At the moment, the stock has a 52-week...
Benzinga · 01/04 15:04
加拿大皇家银行资本将贤哲疗法的评级下调至行业表现,将目标股价上调至86美元
RBC Capital analyst Brian Abrahams downgrades Sage Therapeutics (NASDAQ:SAGE) from Outperform to Sector Perform and raises the price target from $83 to $86.
Benzinga · 01/04 13:43
每日生物技术动向:FDA对Amphastar的通用胰高血糖素致谢,Arcturus接收疫苗数据,对Osmotica做出决定
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28)
Benzinga · 2020/12/29 13:09
每日生物技术动向:Supernus发出积极的ADHD读数,索伦托申请紧急使用授权进行快速COVID-19测试,抑制酶使华尔街首次亮相
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 22)
Benzinga · 2020/12/23 13:29
生物技术日报:诺华获得Adcom的支持,Sio基因数据,两次IPO,BioNTech紧扣中国疫苗供应交易
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 15)
Benzinga · 2020/12/16 12:15
微牛提供丰富的实时SAGE股票新闻,让你可以通过多个平台了解SAGE股票行情最新动态,这些免费的SAGE新闻可以帮助你做出明智投资。
SAGE 简况
SAGE Therapeutics, Inc.是一家进行临床阶段研究的生物制药公司。该公司从事开发和商业化治疗中枢神经系统(CNS)疾病的药物。其首款候选药SAGE-547是一种四氢孕酮静脉内制剂,并且是GABAA受体突触和突触外调节神经类固醇药物。 其候选药物SAGE-217和SAGE-689也靶向GABAA受体系统。该公司致力于开发中枢神经系统突触和突触外受体选择性别构调节药物。该公司致力于通过其化学平台进行内源性或改性合成神经活性类固醇化合物的化学结构的研发。这些内源性或改性合成神经活性类固醇化合物是GABAA或N-Methyl-D-aspartic acid或N-Methyl-D-aspartate(NMDA)受体的别构调节剂。SAGE-718是NMDA受体计划中确定的用于研究开发的候选药物。